Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases

Micic D., Komaki Y., Alavanja A., Et al., Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies, J Clin Gastroenterol, 53, 1, pp. e1-e11, (2019)

Dayer J.M., Choy E., Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor, Rheumatology (Oxford), 49, 1, pp. 15-24, (2010)

Kastrati K., Aletaha D., Burmester G.R., Et al., A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases, RMD Open, 8, 2, (2022)

Rutherford A.I., Subesinghe S., Hyrich K.L., Et al., Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British society for Rheumatology biologics register for rheumatoid arthritis, Ann Rheum Dis, 77, 6, pp. 905-910, (2018)

Pawar A., Desai R.J., Solomon D.H., Et al., Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study, Ann Rheum Dis, 78, 4, pp. 456-464, (2019)

Cantini F., Nannini C., Niccoli L., Et al., Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics, Mediators Inflamm, 2017, (2017)

Jung S.M., Han M., Kim E.H., Et al., Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018, Arthritis Res Ther, 24, 1, (2022)

Koike T., Harigai M., Inokuma S., Et al., Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients, Ann Rheum Dis, 70, 12, pp. 2148-2151, (2011)

MacKenna B., Kennedy N.A., Mehrkar A., Et al., Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform, Lancet Rheumatol, 4, 7, pp. e490-e506, (2022)

Group R.C., Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 10285, pp. 1637-1645, (2021)

Micic D., Komaki Y., Alavanja A., Et al., Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies, J Clin Gastroenterol, 53, 1, pp. e1-e11, (2019)

Dayer J.M., Choy E., Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor, Rheumatology (Oxford), 49, 1, pp. 15-24, (2010)

Kastrati K., Aletaha D., Burmester G.R., Et al., A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases, RMD Open, 8, 2, (2022)

Rutherford A.I., Subesinghe S., Hyrich K.L., Et al., Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British society for Rheumatology biologics register for rheumatoid arthritis, Ann Rheum Dis, 77, 6, pp. 905-910, (2018)

Pawar A., Desai R.J., Solomon D.H., Et al., Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study, Ann Rheum Dis, 78, 4, pp. 456-464, (2019)

Cantini F., Nannini C., Niccoli L., Et al., Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics, Mediators Inflamm, 2017, (2017)

Jung S.M., Han M., Kim E.H., Et al., Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018, Arthritis Res Ther, 24, 1, (2022)

Koike T., Harigai M., Inokuma S., Et al., Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients, Ann Rheum Dis, 70, 12, pp. 2148-2151, (2011)

MacKenna B., Kennedy N.A., Mehrkar A., Et al., Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform, Lancet Rheumatol, 4, 7, pp. e490-e506, (2022)

Group R.C., Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 10285, pp. 1637-1645, (2021)